Dopamine is a catecholamine neurotransmitter that mediates physiological functions in the central and peripheral nervous systems. Binding of dopamine to the dopamine D2 receptor elicits intracellular signaling implicated in various neurological disorders such as Parkinson’s disease (PD) and schizophrenia. Drugs targeting the dopamine D2 receptor have been on the market since the 1960s for the treatment of PD and schizophrenia. However, many are non-specific, act on multiple pharmacological targets, and excessively engage the D2  receptor, thereby leading to poor tolerability and unwanted side effects.

The technology herein describes a novel class of compounds that selectively target the dopamine D2 receptor. It comprises six newly identified chemical structures that have a high affinity for the dopamine D2 receptor. Improved affinity towards the D2 receptor will allow selective activation (agonist) or blocking (antagonist) of the receptor, which may improve safety and efficacy.

Potential Application

This technology can be used as a new treatment for PD, schizophrenia, and similar neurological disorders. A more selective D2 therapy will provide superior efficacy, reduce side effects and improve treatment outcomes as compared to current FDA approved treatments.

Opportunity

Worldwide, more than 60 million people are suffering from PD and schizophrenia, with over 1.5 million newly diagnosed patients every year.  The global market size for PD and schizophrenia is expected to exceed $25 billion by the mid-2020s. New drug approvals, increased emphasis on the treatment of neurological disorders, and significant investment by pharmaceutical companies are driving the rapid growth of the market. If further development of this technology yields a safe and efficacious drug with benefits over currently approved and pipeline drugs, it could become a lucrative asset with potential across many neurological disorders.

Rowan University is looking for a partner for further development and commercialization of this technology through a license.